Drugs & Aging

, Volume 29, Issue 3, pp 243–248 | Cite as

Abiraterone Acetate: A Guide to Its Use in Metastatic Castration-Resistant Prostate Cancer

  • Lesley J. Scott
  • Lily P. H. Yang
  • Katherine A. Lyseng-Williamson
Adis Drug Clinical Q&A

Abstract

Oral abiraterone acetate (Zytiga®), a selective cytochrome P450 17A1 enzyme inhibitor, is used in combination with prednisone or prednisolone to treat patients with metastatic castration-resistant prostate cancer (CRPC) who have previously received docetaxel-containing chemotherapy. In a clinical trial in patients with CRPC, abiraterone acetate plus prednisone significantly prolonged overall survival, the time to prostate-specific antigen progression and progression-free survival compared with placebo plus prednisone.

Notes

Acknowledgements and Disclosures

This article was adapted from Drugs 2011; 71 (15): 2067–77,[1] and was reviewed by: E. Obarcanin, Sarajevo, Bosnia and Herzegovina; N. Reynolds, Auckland City Hospital, Auckland, New Zealand; S. Saluja, Consultant in Internal Medicine, Saran Ashram, Agra, India.

The preparation of this article was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the articles. Changes resulting from comments received were made by the authors on the basis of scientific and editorial merit.

References

  1. 1.
    Yang LPH. Abiraterone acetate: in metastatic castration-resistant prostate cancer. Drugs 2011; 71(15): 2067–77PubMedCrossRefGoogle Scholar
  2. 2.
    Horwich A, Parker C, Bangma C, et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21Suppl. 5: v129–33PubMedCrossRefGoogle Scholar
  3. 3.
    NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™): prostate cancer (version 4.2011). Fort Washington (PA): National Comprehensive Cancer Network, 2011Google Scholar
  4. 4.
    Mottet N, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011 Apr; 59(4): 572–83PubMedCrossRefGoogle Scholar
  5. 5.
    Sartor AO. Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space. J Hematol Oncol 2011 Apr 23; 4(1): 18PubMedCrossRefGoogle Scholar
  6. 6.
    Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004 Mar 15; 22(6): 1025–33PubMedCrossRefGoogle Scholar
  7. 7.
    Zytiga 250mg tablets: summary of product characteristics. London: European Medicines Agency, 2011 Dec 14Google Scholar
  8. 8.
    Zytiga™ (abiraterone acetate) oral tablets: US prescribing information. Horsham (PA): Centocor Ortho Biotech Inc., 2011 AprGoogle Scholar
  9. 9.
    de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011 May 26; 364(21): 1995–2005PubMedCrossRefGoogle Scholar
  10. 10.
    Scher HI, Heller G, Molina A, et al. Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): planned final analysis (FA) of COU-AA-301, a randomized double-blind, placebo-controlled phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel [abstract no. LBA4517]. J Clin Oncol 2011 Jun 20; 29(18 Suppl.)Google Scholar
  11. 11.
    Fizazi K, Scher HI, Molina A, et al. Final overall survival (OS) analysis of COU-AA-301, a phase 3 study of abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) pretreated with docetaxel [abstract no. 7000]. 2011 European Multi-disciplinary Cancer Congress; 2011 Sep 23–27; StockholmGoogle Scholar
  12. 12.
    Bianchini D. Durable disease control, safety, and tolerability of abiraterone acetate (AA) in advanced castration-resistant prostate cancer (CRPC) [abstract no. 4672]. J Clin Oncol 2010 May 20; 28(15 Suppl.)Google Scholar
  13. 13.
    Cougar Biotechnology Inc. Abiraterone acetate in asymptomatic or mildly symptomatic patients with metastatic castration-resistant prostate cancer [ClinicalTrials.gov identifier NCT00887198]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Sep 16]

Copyright information

© Adis Data Information BV 2012

Authors and Affiliations

  • Lesley J. Scott
    • 1
  • Lily P. H. Yang
    • 1
  • Katherine A. Lyseng-Williamson
    • 1
  1. 1.AdisMairangi Bay, North Shore 0754, AucklandNew Zealand

Personalised recommendations